GRPH - Graphite Bio: An Important Stock To Track In The Gene Editing Space
- Graphite Bio Initiated the phase 1/2 CEDAR trial using GPH101 for a potential curative treatment of patients with severe sickle-cell disease.
- First patient in phase 1/2 CEDAR trial will be dosed in the 1st half of 2022 and the first set of results are expected in the 2nd half of 2022.
- It is estimated that the Sickle Cell Disease market is estimated to be worth $5.5 billion by 2023.
- If proof of concept achieved for GPH101 in Sickle-cell disease, then other indications to be tackled are Gaucher Disease and XSCID; IND filings for one of these not anticipated until mid-2023.
For further details see:
Graphite Bio: An Important Stock To Track In The Gene Editing Space